Loading
Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.
Alisertib is listed on ClinicalTrials.gov as an intervention in 5 registered phase 2 trials sponsored by Puma Biotechnology, Inc., in small-cell lung cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.
1.Alisertib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Alisertib" OR ABSTRACT:"Alisertib" OR TITLE:"PB-8237" OR ABSTRACT:"PB-8237" OR TITLE:"MLN8237" OR ABSTRACT:"MLN8237") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alisertib, not a curated reading list.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer and the tags pipeline, registry-only.